Prospects for the use of ATR inhibitors to treat cancer

Jill M. Wagner, Scott H Kaufmann

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

Original languageEnglish (US)
Pages (from-to)1311-1334
Number of pages24
JournalPharmaceuticals
Volume3
Issue number5
DOIs
StatePublished - 2010

Fingerprint

Phosphotransferases
DNA Damage
Neoplasms
Down-Regulation

Keywords

  • ATM
  • ATR
  • Chemotherapy
  • Chk1
  • Replication checkpoint

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science

Cite this

Prospects for the use of ATR inhibitors to treat cancer. / Wagner, Jill M.; Kaufmann, Scott H.

In: Pharmaceuticals, Vol. 3, No. 5, 2010, p. 1311-1334.

Research output: Contribution to journalArticle

Wagner, Jill M. ; Kaufmann, Scott H. / Prospects for the use of ATR inhibitors to treat cancer. In: Pharmaceuticals. 2010 ; Vol. 3, No. 5. pp. 1311-1334.
@article{f20a6f6f632e4d30979de334fdd588df,
title = "Prospects for the use of ATR inhibitors to treat cancer",
abstract = "ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.",
keywords = "ATM, ATR, Chemotherapy, Chk1, Replication checkpoint",
author = "Wagner, {Jill M.} and Kaufmann, {Scott H}",
year = "2010",
doi = "10.3390/ph3051311",
language = "English (US)",
volume = "3",
pages = "1311--1334",
journal = "Pharmaceuticals",
issn = "1424-8247",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "5",

}

TY - JOUR

T1 - Prospects for the use of ATR inhibitors to treat cancer

AU - Wagner, Jill M.

AU - Kaufmann, Scott H

PY - 2010

Y1 - 2010

N2 - ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

AB - ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

KW - ATM

KW - ATR

KW - Chemotherapy

KW - Chk1

KW - Replication checkpoint

UR - http://www.scopus.com/inward/record.url?scp=77954938500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954938500&partnerID=8YFLogxK

U2 - 10.3390/ph3051311

DO - 10.3390/ph3051311

M3 - Article

AN - SCOPUS:77954938500

VL - 3

SP - 1311

EP - 1334

JO - Pharmaceuticals

JF - Pharmaceuticals

SN - 1424-8247

IS - 5

ER -